RecruitingNon-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Eligible age

18+ yrs

Accepts

All genders

Locations

13 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

Sponsor: Revolution Medicines, Inc.

✓ Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).
✓ Treatment naive or have received prior standard therapy appropriate for tumor type and stage
✓ Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
✓ Adequate organ function

✕ Primary central nervous system (CNS) tumors
✕ Active, untreated brain metastases
✕ Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
✕ History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy
✕ Other inclusion/exclusion criteria may apply.